HOUSTON , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation of preclinical data highlighting the potential of neoantigen-specific TCR-T cells for the treatment of solid tumors at the Society for Immunotherapy of
HOUSTON , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced financial results for the third quarter ended September 30, 2021 and provided a business update. “I am impressed by the quality and dedication of our team at Ziopharm
HOUSTON , Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021 , after the close of U.S. markets.
• Over 50% reduction in personnel • Cost reductions expected to extend the cash runway into the first half of 2023 • The first patient in its TCR-T Library Phase I/II clinical trial is expected to be dosed in 1H2022 BOSTON and HOUSTON , Sept. 27, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc.
BOSTON and HOUSTON , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that Kevin S. Boyle , Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual investor conferences: 2021 Wells Fargo
Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles Strong track record of successfully guiding companies and creating shareholder value through disciplined capital management and achievement of milestones Raffaele Baffa MD, Ph.D.
Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company’s manufacturing facility and presentation of favorable preclinical data Closed venture debt financing with Silicon Valley Bank , strengthening balance sheet and e xtending cash runway into the
BOSTON , July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9 , at 4:30 p.m. EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2021 .
BOSTON , May 24, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, today announced that Company management will participate in two upcoming investor conferences:
– Highlighted distinctive cellular therapy program, market opportunity and value proposition – Shared optimistic outlook and commitment to deliver value to shareholders – Encouraged by overwhelming vote of shareholders in favor of the Company proposals on all matters BOSTON , May 19, 2021